not tagged
abbott
['triluminate', 'cardio']
triluminate trial majority patients female. &gt;50% baseline torrential tr. primary endpoint met primarily driven by improved qol. 87% reduction to moderate or less tr. reduction sustained at 1 year. safe. slda 7% not affecting tr severity #acc2023 #wccardio 
Structural Heart Disease Fellow, Minneapolis Heart Institute. Trained @RushMedical @WCMCardsFellows Tweets are my own.